Enfermedad de Chagas, alternativas emergentes para la búsqueda de tratamientos tripanocidas

Autores/as

  • Daniel Andrés Pardo Rodríguez Pontificia Universidad Javeriana
  • Jorge Eliecer Robles Camargo Pontificia Universidad Javeriana
  • Claudia Liliana Cuervo Patiño Universidad del Tolima

Palabras clave:

Enfermedad de Chagas, Trypanosoma cruzi, tratamiento, productos naturales, reposicionamiento de fármacos

Resumen

Trypanosoma cruzi es el agente etiológico de la enfermedad de Chagas también conocida como tripanosomiasis americana, enfermedad que hace parte del grupo de enfermedades tropicales desatendidas. El tratamiento de la infección se basa únicamente en dos fármacos: Nifurtimox y Benznidazol. Ambos fármacos son controvertidos debido a que presentan varios problemas asociados a la toxicidad del medicamento, al tiempo de tratamiento y a la presencia de aislados con diferente grado de susceptibilidad, entre otras. Por tanto, se hace necesario la búsqueda de nuevas alternativas para el tratamiento de la ECh. Aproximaciones como el uso de productos naturales etnobotánicos y el reposicionamiento de fármacos ya existentes, pueden ser fuente de nuevas alternativas para el desarrollo a futuro de tratamientos que sean inocuos y efectivos. Esta revisión proporciona las principales características de la enfermedad de Chagas. Adicionalmente, presenta dos aproximaciones metodológicas para la búsqueda de nuevos compuestos tripanocidas.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Alrajhi, A. A., Ibrahim, E. A., De Vol, E. B., Khairat, M., Faris, R. M., & Maguire, J. H. (2002). Fluconazole for the Treatment of Cutaneous Leishmaniasis Caused by Leishmania major . New England Journal of Medicine, 346(12), 891–895. https://doi.org/10.1056/nejmoa011882

Beer, M. F., Frank, F. M., Germán Elso, O., Ernesto Bivona, A., Cerny, N., Giberti, G., Luis Malchiodi, E., Susana Martino, V., Alonso, M. R., Patricia Sülsen, V., & Cazorla, S. I. (2016). Trypanocidal and leishmanicidal activities of flavonoids isolated from Stevia satureiifolia var. satureiifolia. Pharmaceutical Biology, 54(10), 2188–2195. https://doi.org/10.3109/13880209.2016.1150304

Bern, C. (2015). Chagas’ Disease. New England Journal of Medicine, 373(5), 456–466. https://doi.org/10.1056/NEJMra1410150

Bern, C., Montgomery, S. P., Herwaldt, B. L., Marin-neto, J. A., Maguire, J. H., Acquatella, H., Morillo, C., Gilman, R. H., Reyes, P. A., & Salvatella, R. (2007). Evaluation and Treatment of Chagas Disease in the United States A Systematic Review. Clinical Review, 298(18), 2171–2181. https://academic.oup.com/cid/article-lookup/doi/10.1086/605091

Bonney, K. M., Luthringer, D. J., Kim, S. A., Garg, N. J., & Engman, D. M. (2019). Pathology and pathogenesis of Chagas heart disease. Annu. Rev. Pathol. Mech. Dis., 14, 421–447.

Burki, T. (2011). Production of drugs for Chagas disease predicted to fall short. The Lancet Infectious Diseases, 11(12), 901–902. https://doi.org/10.1016/S1473-3099(11)70327-9

Bustamante, J. M., & Tarleton, R. L. (2014). Potential new clinical therapies for Chagas disease. Expert Review of Clinical Pharmacology, 7(3), 317–325. https://doi.org/10.1586/17512433.2014.909282

Castro, J. A., deMecca, M. M., & Bartel, L. C. (2006). Toxic Side Effects of Drugs Used to Treat Chagas’ Disease (American Trypanosomiasis). Human & Experimental Toxicology, 25(8), 471–479. https://doi.org/10.1191/0960327106het653oa

De Mesquita, M. L., Desrivot, J., Bories, C., Fournet, A., De Paula, J. E., Grellier, P., & Espindola, L. S. (2005). Antileishmanial and trypanocidal activity of Brazilian Cerrado plants. Memorias Do Instituto Oswaldo Cruz, 100(7), 783–787. https://doi.org/10.1590/S0074-02762005000700019

Dias, J. C. P., Coura, J. R., & Yasuda, M. A. S. (2014). The present situation, challenges, and perspectives regarding the production and utilization of effective drugs against human Chagas disease. In Revista da Sociedade Brasileira de Medicina Tropical (Vol. 47, Issue 1). https://doi.org/10.1590/0037-8682-0248-2013

Frank, F. M., Ulloa, J., Cazorla, S. I., Maravilla, G., Malchiodi, E. L., Grau, A., Martino, V., Catalán, C., & Muschietti, L. V. (2013). Trypanocidal activity of Smallanthus sonchifolius: Identification of active sesquiterpene lactones by bioassay-guided fractionation. Evidence-Based Complementary and Alternative Medicine. https://doi.org/10.1155/2013/627898

Kessler, R. L., Soares, M. J., Probst, C. M., Auré, M., Krieger, L., & Goldberg, A. C. (2013). Trypanosoma cruzi Response to Sterol Biosynthesis Inhibitors: Morphophysiological Alterations Leading to Cell Death. PLoS ONE, 8(1). https://doi.org/10.1371/journal.pone.0055497

Lidani, K. C. F., Andrade, F. A., Bavia, L., Damasceno, F. S., Beltrame, M. H., Messias-Reason, I. J., & Sandri, T. L. (2019). Chagas Disease: From Discovery to a Worldwide Health Problem. Frontiers in Public Health, 7(July), 1–13. https://doi.org/10.3389/fpubh.2019.00166

Lionta, E., Spyrou, G., Vassilatis, D. K., & Cournia, Z. (2014). Structure-based virtual screening for drug discovery: principles, applications and recent advances. Current Topics in Medicinal Chemistry, 14(16), 1923–1938. https://doi.org/10.2174/1568026614666140929124445

Lopera Valle, J. S., Rojas Jiménez, S., & Mejía Ochoa, M. (2013). Actividad tripanocida de plantas latinoamericanas, una futura alternativa terapéutica para la Enfermedad de Chagas. Rev. Ibero-Latinoam. Parasitol., 72(72), 22–30.

Manne-Goehler, J., Umeh, C. A., Montgomery, S. P., & Wirtz, V. J. (2016). Estimating the Burden of Chagas Disease in the United States. PLoS Neglected Tropical Diseases, 10(11), 1–7. https://doi.org/10.1371/journal.pntd.0005033

Marín, C., Ramírez-Macías, I., López-Céspedes, A., Olmo, F., Villegas, N., Díaz, J. G., Rosales, M. J., Gutiérrez-Sánchez, R., & Sánchez-Moreno, M. (2011). In vitro and in vivo trypanocidal activity of flavonoids from Delphinium staphisagria against chagas disease. Journal of Natural Products, 74(4), 744–750. https://doi.org/10.1021/np1008043

Mejía-Jaramillo, A. M., Fernández, G. J., Montilla, M., Nicholls, R. S., & Triana-Chávez, O. (2012). Sensibilidad al benzonidazol de cepas de Trypanosoma cruzi sugiere la circulación de cepas naturalmente resistentes en Colombia. Biomédica, Revista Del Instituto Nacional de Salud., 32(2), 196–205. https://doi.org/10.1590/S0120-41572012000300007

Momeni, A. Z., Aminjavaheri, M., & Omidghaemi, M. R. (2003). Treatment of cutaneous leishmaniasis with ketoconazole cream. Journal of Dermatological Treatment, 14(1), 26–29. https://doi.org/10.1080/09546630305552

Ndjonka, D., Rapado, L. N., Silber, A. M., Liebau, E., & Wrenger, C. (2013). Natural products as a source for treating neglected parasitic diseases. In International Journal of Molecular Sciences (Vol. 14, Issue 2). https://doi.org/10.3390/ijms14023395

Nosengo, N. (2016). New tricks for old drugs. Nature, 534(7607), 314–316. https://doi.org/10.1038/534314a

Ogungbe, I. V., & Setzer, W. N. (2016). The Potential of Secondary Metabolites from Plants as Drugs or Leads against Protozoan Neglected Diseases-Part III: In-Silico Molecular Docking Investigations. Molecules, 21(10), 1–48. https://doi.org/10.3390/molecules21101389

Patterson, S., & Wyllie, S. (2014). Nitro drugs for the treatment of trypanosomatid diseases: Past, present, and future prospects. Trends in Parasitology, 30(6), 289–298. https://doi.org/10.1016/j.pt.2014.04.003

Pérez-Molina, J. A., & Molina, I. (2017). Chagas disease. The Lancet, 6736(17), 1–13. https://doi.org/10.1016/S0140-6736(17)31612-4

Pérez-Molina, J. A., & Molina, I. (2018). Chagas disease. The Lancet, 391(10115), 82–94. https://doi.org/10.1016/S0140-6736(17)31612-4

Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., Norris, A., Sanseau, P., Cavalla, D., & Pirmohamed, M. (2019). Drug repurposing: progress, challenges and recommendations. Nature Reviews. Drug Discovery, 18(1), 41–58. https://doi.org/10.1038/nrd.2018.168

Rassi, A., Rassi, A., & Marcondes de Rezende, J. (2012). American Trypanosomiasis (Chagas Disease). Infectious Disease Clinics of North America, 26(2), 275–291. https://doi.org/10.1016/j.idc.2012.03.002

Rassi, A., Rassi, A., & Marin-Neto, J. A. (2010). Chagas disease. The Lancet, 375(9723), 1388–1402. https://doi.org/10.1016/S0140-6736(10)60061-X

Ribeiro, A. L., Nunes, M. P., Teixeira, M. M., & Rocha, M. O. C. (2012). Diagnosis and management of Chagas disease and cardiomyopathy. Nature Reviews Cardiology, 9(10), 576–589. https://doi.org/10.1038/nrcardio.2012.109

Rodriguez, J. B., Falcone, B. N., & Szajnman, S. H. (2016). Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015). Expert Opinion on Therapeutic Patents, 26(9), 993–1015. https://doi.org/10.1080/13543776.2016.1209487

Sánchez-Valdéz, F. J., Padilla, A., Wang, W., Orr, D., & Tarleton, R. L. (2018). Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure. ELife, 7, e34039. https://doi.org/10.7554/eLife.34039

Shikanai-Yasuda, M. A., & Carvalho, N. B. (2012). Oral transmission of chagas disease. Clinical Infectious Diseases, 54(6), 845–852. https://doi.org/10.1093/cid/cir956

Sülsen, V. P., Puente, V., Papademetrio, D., Batlle, A., Martino, V. S., Frank, F. M., & Lombardo, M. E. (2016). Mode of action of the sesquiterpene lactones psilostachyin and psilostachyin C on Trypanosoma cruzi. PLoS ONE, 11(3), 1–14. https://doi.org/10.1371/journal.pone.0150526

Sundar, S., & Jaya, C. (2010). Liposomal amphotericin B and leishmaniasis: Dose and response. Journal of Global Infectious Diseases, 2(2), 159–166. https://doi.org/10.4103/0974-777x.62886

Trochine, A., Creek, D. J., Faral-Tello, P., Barrett, M. P., & Robello, C. (2014). Benznidazole Biotransformation and Multiple Targets in Trypanosoma cruzi Revealed by Metabolomics. PLoS Neglected Tropical Diseases, 8(5). https://doi.org/10.1371/journal.pntd.0002844

Urbina, J. A. (2010). Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches. Acta Tropica, 115(1–2), 55–68. https://doi.org/10.1016/j.actatropica.2009.10.023

Urbina, J. A. (2015). Recent clinical trials for the etiological treatment of chronic chagas disease: Advances, challenges and perspectives. Journal of Eukaryotic Microbiology, 62(1), 149–156. https://doi.org/10.1111/jeu.12184

Valencia, L., Muñoz, D. L., Robledo, S. M., & Echeverri, F. (2011). Actividad tripanocida y citotóxica de extractos de plantas Colombianas. Biomédica, 31, 552–559. https://doi.org/10.1590/S0120-41572011000400010

Willett, P. (2006). Similarity-based virtual screening using 2D fingerprints. Drug Discovery Today, 11(23), 1046–1053. https://doi.org/10.1016/j.drudis.2006.10.005

World Health Organization. (2015). Weekly epidemiological record (WER). Who, 90(6), 33–40. https://doi.org/10.1016/j.actatropica.2012.04.013.

World Health Organization. (2021). Chagas disease (also known as American tripanosomiasis) fact sheet, 1 April 2021.

Descargas

Publicado

2022-10-13

Cómo citar

Pardo Rodríguez, D. A. ., Robles Camargo, J. E. ., & Cuervo Patiño, C. L. . (2022). Enfermedad de Chagas, alternativas emergentes para la búsqueda de tratamientos tripanocidas. REVISTA SAYWA, 3(4), 22-32. Recuperado a partir de https://revistas.uan.edu.co/index.php/saywa/article/view/1007

Número

Sección

Ciencia Aplicada